Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | COMT | P21964 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31470291 | 0.82 | GAA (0.33) | GAAATML3MBTL1KMT2ACOMT | |
| SCHEMBL28420010 | 0.82 | GAA (0.33) | GAAATML3MBTL1KMT2ACOMT | |
| SCHEMBL8012346 | 0.81 | HSD11B1 (0.43) | GAAATML3MBTL1COMTHSD11B1 | |
| SCHEMBL7602038 | 0.77 | HSD11B1 (0.33) | COMTHSD11B1 | |
| SCHEMBL7537868 | 0.75 | RAB9A (0.48) | GAAL3MBTL1KMT2ANPC1RAB9A | |
| SCHEMBL8570147 | 0.74 | GAA (0.33) | GAAATML3MBTL1KMT2ACOMT | |
| SCHEMBL4678151 | 0.73 | COMT (0.40) | GAAATML3MBTL1COMTNPC1 | |
| SCHEMBL6979611 | 0.73 | GAA (0.33) | GAAATML3MBTL1COMTGRM2 | |
| SCHEMBL7929963 | 0.73 | GAA (0.31) | GAAATMCOMT | |
| SCHEMBL4678823 | 0.72 | PPOX (0.43) | GAAGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156285-A1 | Novel herbicides | KUNZ WALTER (CH) | 2002-10-24 | — | — | US | disclosed |
| US-6369002-B1 | HETERO IS PYRIMIDINE OR PYRIDAZINE; 1-(3-FLUORO-5-CHLORO PYRIDIN-2-YL)-3-METHYL-4-TRIFLUOROMETHYLPYRIMIDIN-2,6-DIONE | SYNGENTA CROP PROPERTIES, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-1076656-A2 | N-HETEROARYL-SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | Novartis AG (CH) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999055693-A2 | N-HETEROARYL-SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156285-A1 | Novel herbicides | DDT, CBR1, CBR3 | GAA 3410/4885ATM 4080/4885L3MBTL1 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.